Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease.

[1]  Markku Peltonen,et al.  Long-Term Effect of Bariatric Surgery on Liver Enzymes in the Swedish Obese Subjects (SOS) Study , 2013, PloS one.

[2]  B. Schmidt,et al.  Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. , 2012, Cytokine.

[3]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[4]  M. Swain,et al.  Liver-brain inflammation axis. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[5]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[6]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  E. Bugianesi,et al.  Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[8]  J. Schwimmer,et al.  Symptoms and quality of life in obese children and adolescents with non‐alcoholic fatty liver disease , 2010, Alimentary pharmacology & therapeutics.

[9]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[10]  Nick V. Grishin,et al.  A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis , 2009, The Journal of Biological Chemistry.

[11]  S. Sookoian,et al.  A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity , 2009, Journal of Lipid Research.

[12]  N. Lundbom,et al.  Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. , 2009, Gastroenterology.

[13]  Kathryn A. Lee,et al.  Preliminary Evidence of a Genetic Association Between Tumor Necrosis Factor Alpha and the Severity of Sleep Disturbance and Morning Fatigue , 2009, Biological research for nursing.

[14]  B. McMahon,et al.  Chronic Liver Disease among Alaska-Native People, 2003–2004 , 2009, The American Journal of Gastroenterology.

[15]  K. Kasturi,et al.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[17]  B. Bell,et al.  Chronic Liver Disease Among Two American Indian Patient Populations in the Southwestern United States, 2000-2003 , 2008, Journal of clinical gastroenterology.

[18]  H. Sørensen,et al.  Comorbidity and survival of Danish cirrhosis patients: A nationwide population‐based cohort study , 2008, Hepatology.

[19]  S. Taylor-Robinson,et al.  Non-invasive means of measuring hepatic fat content. , 2008, World journal of gastroenterology.

[20]  Yoosoo Chang,et al.  Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. , 2008, Metabolism: clinical and experimental.

[21]  L. Gerber,et al.  Health‐related quality of life in patients with non‐alcoholic fatty liver disease , 2007, Alimentary pharmacology & therapeutics.

[22]  F. Durazo,et al.  Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management. , 2007, Nutrition reviews.

[23]  A. Baranova,et al.  Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease , 2007, Obesity surgery.

[24]  H. J. de Silva,et al.  How should we manage patients with non‐alcoholic fatty liver disease in 2007? , 2007, Journal of gastroenterology and hepatology.

[25]  P. Angulo,et al.  Obesity and nonalcoholic fatty liver disease. , 2007, Nutrition reviews.

[26]  Manisha Talim,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[27]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[28]  K. Lindor,et al.  Nonalcoholic fatty liver disease , 2005, Canadian Medical Association Journal.

[29]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[30]  A. Sanyal,et al.  Clinical aspects of fatty liver disease. , 2004, Seminars in liver disease.

[31]  Ronald M Peshock,et al.  The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. , 2004, The American journal of cardiology.

[32]  J. Dixon,et al.  Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss , 2004, Hepatology.

[33]  L. Bouter,et al.  How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.

[34]  S. Paul,et al.  Symptom clusters and their effect on the functional status of patients with cancer. , 2001, Oncology nursing forum.

[35]  G. Guyatt,et al.  Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease , 1999, Gut.

[36]  F. Suppe,et al.  The middle-range theory of unpleasant symptoms: an update. , 1997, ANS. Advances in nursing science.

[37]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[38]  S. T. Hegyvary.  Patient Care Outcomes Related to Management of Symptoms , 1993, Annual Review of Nursing Research.

[39]  F. Schaffner,et al.  Fatty liver hepatitis and cirrhosis in obese patients. , 1979, The American journal of medicine.

[40]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[41]  David Kershenobich,et al.  Variant in PNPLA3 is associated with alcoholic liver disease , 2010, Nature Genetics.

[42]  M. Iacovino,et al.  Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent , 2010, International Journal of Obesity.

[43]  W. Salt,et al.  Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. , 2004, Journal of insurance medicine.

[44]  J. V. van Meerbeeck,et al.  Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[45]  T. Armstrong.  Symptoms experience: a concept analysis. , 2003, Oncology nursing forum.

[46]  Eugene R. Schiff,et al.  Schiff's diseases of the liver , 1999, Gastroenterology.

[47]  H. Scher,et al.  The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. , 1994, European journal of cancer.

[48]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[49]  D. Polit-O'hara,et al.  Nursing Research: Principles and Methods , 1978 .